Form 8-K - Current report:
SEC Accession No. 0001193125-25-028650
Filing Date
2025-02-18
Accepted
2025-02-18 16:31:47
Documents
14
Period of Report
2025-02-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d889348d8k.htm   iXBRL 8-K 34959
2 EX-99.1 d889348dex991.htm EX-99.1 28947
  Complete submission text file 0001193125-25-028650.txt   197200

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA stok-20250214.xsd EX-101.SCH 2880
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE stok-20250214_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE stok-20250214_pre.xml EX-101.PRE 10832
16 EXTRACTED XBRL INSTANCE DOCUMENT d889348d8k_htm.xml XML 3497
Mailing Address 45 WIGGINS AVENUE BEDFORD MA 01730
Business Address 45 WIGGINS AVENUE BEDFORD MA 01730 781-430-8200
Stoke Therapeutics, Inc. (Filer) CIK: 0001623526 (see all company filings)

EIN.: 471144582 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38938 | Film No.: 25635519
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)